Search Results
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed using OncoPrecision's proprietary discovery engine,
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 para la leucemia monocítica
un conjugado anticuerpo-fármaco (ADC) pionero en su clase, diseñado para actuar exclusivamente sobre CD64, un receptor restringido a mieloides que se expresa ampliamente en la LMMC y la leucemia mieloide aguda M4/M5, incluyendo subpoblaciones altamente resistentes. El ADC se desarrolló utilizando el motor
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision gibt an, dass es auf der 67. ASH-Jahrestagung eine mündliche Präsentation zu ONC001, einem erstklassigen CD64-gerichteten ADC für monozytäre Leukämie, durchführen wird
ONC001 ist ein neuartiges Antikörper-Wirkstoff-Konjugat (ADC), das speziell auf CD64 abzielt, einen myeloischen Rezeptor, der bei CMML und akuter myeloischer Leukämie vom Typ M4/M5, einschließlich hochresistenter Subtypen, weit verbreitet ist. Das ADC wurde unter Verwendung der proprietären Forschungsplattform
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET Lors de la 67e réunion annuelle de l'ASH, OncoPrecision a annoncé la présentation orale de ONC001, un conjugué anticorps-médicament ciblant le récepteur CD64, premier de sa catégorie, pour la leucémie monocytaire.
en tant que cible thérapeutique. Notre plateforme a dévoilé qu'une modalité ADC est la voie optimale pour y parvenir ».Détails de la présentation oraleTitre : ONC001 : premier ADC ciblant le récepteur CD64 pour le traitement de la leucémie monocytaire, développé
More news about: OncoPrecision Corporation
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
(TAGRISSO®, AstraZeneca) an EGFR tyrosine kinase inhibitor (TKI), second-line Dato-DXd (Datroway®, AstraZeneca/Daiichi Sankyo) a Trop-2 ADC, and third-line amivantamab (Rybrevant®, Johnson & Johnson) an EGFR-cMET bispecific had sales of approximately $7 billion in 2024 with
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:00 ET Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
statements relating to: the potential therapeutic value and market opportunity for the Company's ADC portfolio; the anticipated timing of the Company's development of its portfolio of ADC assets, including moving the ADC assets into the clinic; expectations regarding the beneficial characteristics, safety, efficacy,
More news about: Whitehawk Therapeutics, Inc.
Dec 01, 2025, 06:00 ET IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies. We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026," said Yujiro S. Hata, President and
More news about: IDEAYA Biosciences, Inc.
Nov 28, 2025, 08:00 ET BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinomaThe company enables seamless Europe–China tech transfer and faster biologics development through an integrated,
More news about: BioDlink Biopharm Co., Ltd.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 26, 2025, 12:43 ET CaliberMRI announces release of the qDisc, a new quantitative MRI phantom for added functionality of the Medium ACR Phantom
compatible with the Medium ACR phantom. CaliberMRI's qDisc (quantitative Dual Imaging Standardization Compartment) Model 141 allows sites to baseline T1, T2, ADC, and Proton Density in a single slice when scanning the Medium ACR phantom. The qDisc includes the Company's patented MR readable LC Thermometer and
More news about: CaliberMRI, Inc.
Nov 26, 2025, 08:00 ET Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual
More news about: Whitehawk Therapeutics, Inc.
Nov 25, 2025, 09:00 ET Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for advanced solid tumors. This Phase I/II clinical trial (CTR20254163) aims to evaluate the safety, tolerability, pharmacokinetic
More news about: Mabwell
Nov 25, 2025, 08:00 ET GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation
partnership with MTPC," said Ying Gong, Ph.D., Chief Business Officer of GV20. "This progress reflects our shared commitment to rapidly advancing innovative ADC therapies for patients with cancer. We look forward to continuing this positive momentum."Under the terms of the agreement, GV20 received an upfront
More news about: GV20 Therapeutics
Nov 24, 2025, 19:42 ET Phrontline Biopharma Raises $60 Million in Pre-A+ Financing to Advance Global Development of Bispecific and Dual-Payload ADCs
Phrontline's differentiated bispecific and dual-payload ADC platforms, its strategically designed pipeline, and its rapidly expanding global development capabilities. Proceeds will support advancement of the company's clinical-stage and preclinical ADC programs, expansion of global clinical operations,
More news about: Phrontline Biopharma
Nov 24, 2025, 08:34 ET GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
Collaboration builds clinical foundation for GNX1021, a first-in-class glycan-directed ADC being developed for gastric cancer patients NEW TAIPEI CITY, Taiwan, Nov. 24, 2025 /PRNewswire/ --
More news about: GlycoNex, Inc.
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 24, 2025, 01:16 ET Le groupe Yatsen ouvre une nouvelle ère pour la science de la beauté à l'échelle mondiale en dévoilant son rapport d'information sur l'innovation dans le domaine de la beauté
de cosmétique, notamment ceux de l'IFSCC, de l'Académie européenne de dermatologie et de vénéréologie (EADV), au Congrès asiatique de dermatologie (ADC) et au Congrès mondial de dermatologie (WCD).Du laboratoire au marché : la science au service de la beautéLe rapport d'information
More news about: Yatsen Holding Limited
Nov 21, 2025, 10:20 ET Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
cancer.2. FibroGen, Inc. (USA)Though historically focused on other indications, FibroGen licensed an antibody-drug conjugate (ADC) FG-3246 targeting CD46 for mCRPC.Early Phase 2 results (PSA50 response ~36% in heavily-pretreated mCRPC) indicate potential in a tough
More news about: DataM Intelligence 4 Market Research LLP
Nov 21, 2025, 08:00 ET BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
market launch of MEIYOUHENG®(Becotatug Vedotin injection) , the world's first EGFR-targeting antibody-drug conjugate (ADC). The launch also represents the first ADC fully manufactured by a CDMO to reach the market in China, underscoring a new level of maturity for the region's biopharmaceutical
More news about: BioDlink Biopharm Co., Ltd.
Nov 20, 2025, 20:00 ET Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition
drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential
More news about: Fosun
Nov 19, 2025, 23:43 ET L'usine de bioconjugués de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, reçoit des certificats de BPF de la MHRA mis à jour
réglementaires de ses clients. En tant qu'installation de développement et de fabrication de conjugués anticorps-médicaments (ADC) dédiée de Piramal Pharma Solutions, Grangemouth offre des solutions complètes pour les bioconjugués, de l'élaboration des procédés à leur industrialisation.
More news about: Piramal Pharma Solutions
Nov 19, 2025, 21:56 ET Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3 x PD-L1 targeted therapy featuring "IO + ADC" dual-effect molecules
More news about: Antengene Corporation Limited
Nov 19, 2025, 15:50 ET La planta de bioconjugados de Piramal Pharma Solutions en Grangemouth recibe certificados GMP de la MHRA
y las presentaciones regulatorias de sus clientes. Como centro de desarrollo y fabricación de conjugados anticuerpo-fármaco (ADC) de Piramal Pharma Solutions, Grangemouth ofrece soluciones integrales para bioconjugados, desde el desarrollo de procesos hasta la ampliación de escala.
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:47 ET Die Biokonjugat-Anlage von Piramal Pharma Solutions in Grangemouth, Großbritannien, erhält aktualisierte MHRA-GMP-Zertifikate
Zulassungsanträge seiner Kunden zu unterstützen. Als spezielle Entwicklungs- und Produktionsstätte für Antikörper-Wirkstoff-Konjugate (ADC) von Piramal Pharma Solutions bietet Grangemouth umfassende Lösungen für Biokonjugate, von der Prozessentwicklung bis zur Skalierung. Der Standort spielt
More news about: Piramal Pharma Solutions
Nov 19, 2025, 15:44 ET Lo stabilimento di bioconiugati di Piramal Pharma Solutions a Grangemouth, nel Regno Unito, riceve i certificati GMP MHRA aggiornati
normative dei propri clienti. In qualità di stabilimento dedicato allo sviluppo e alla produzione di coniugati farmaco-anticorpo (ADC) di Piramal Pharma Solutions, Grangemouth offre soluzioni complete per i bioconiugati, dallo sviluppo del processo all'aumento di scala. Il sito svolge
More news about: Piramal Pharma Solutions